Answers are grounded in this paper and cite their sources.
In vitro study reveals iron oxides catalyze dehydroamino acid formation in model peptides, highlighting a mechanism linking iron accumulation to protein crosslinking in Alzheimer's disease.
The dehydroamino acids (DHAAs) dehydroalanine and dehydrobutyrine are formed in proteins posttranslationally from serine and threonine, respectively. They contain an electrophilic alkene, which reacts readily with nucleophiles by Michael addition, giving rise to a variety of chemical modifications as well as protein crosslinks. Recent work has shown DHAAs and their modifications to be highly prevalent in protein aggregates isolated from brains of Alzheimer's Disease (AD) patients. As there is no human enzyme known to catalyze the formation of DHAAs, this raised the question of how they are produced. We show here that metal oxides, particularly the iron oxides goethite and hematite, efficiently catalyze the formation of DHAAs in model phosphopeptides in vitro under physiologically relevant conditions. Iron oxides are known to accumulate in the human brain with age, and this deposition is enhanced in neurodegenerative disorders like AD. The DHAA formation by heterogeneous catalysis reported here provides a previously unknown mechanism linking iron deposition to protein crosslinking in AD and potentially other neurodegenerative diseases where iron accumulation and protein aggregation co-occur.
No takes yet. Share an insight, caveat, or question.
Markovich et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: